Skip to main content

Table 3 Perception of PrEP among HIV specialists according to their attitude towards PrEP prescription

From: Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists

  Positive Negative Total OR (95% CI)
  216 95 311
I am concerned that PrEP will not be 100% effective (N = 295) Agree 161 (78.9) 77 (84.6) 238 1
Disagree 43 (21.1) 14 (15.4) 57 1.47 (0.76-2.85)
I am concerned about the potential side effects of PrEP (N = 297) Agree 133 (64.9) 75 (81.5) 208 1
Disagree 72 (35.1) 17 (18.5) 89 2.39 (1.31-4.35)
I feel uncomfortable prescribing drugs for new indications unless there is clear evidence of benefit (N = 293) Agree 132 (65.0) 71 (78.9) 203 1
Disagree 71 (35.0) 19 (21.1) 90 2.01 (1.12-3.60)
I am concerned about a low adherence to PrEP* (N = 159) Agree 55 (59.8) 44 (65.7) 99 1
Disagree 37 (40.2) 23 (34.3) 60 1.29 (0.67-2.48)
I do not have time to engage in prevention counselling and PrEP monitoring (N = 290) Agree 22 (11.0) 7 (7.8) 29 1
Disagree 178 (89.0) 83 (92.2) 261 0.68 (0.28-1.66)
The use of PrEP will cause patients to engage in riskier behaviours (N = 297) Agree 145 (70.4) 73 (80.2) 218 1
Disagree 61 (29.6) 18 (19.8) 79 1.71 (0.94-3.10)
The provision of PrEP will result in an increase in sexually transmitted disease incidence among patients (N = 296) Agree 136 (66.7) 67 (72.8) 203 1
Disagree 68 (33.3) 25 (27.2) 93 1.34 (0.78-2.31)
Encourage access to testing and care for HIV infection are more effective measures* (N = 160) Agree 81 (87.1) 64 (95.5) 145 1
Disagree 12 (12.9) 3 (4.5) 15 3.16 (0.86-11.68)
Non-biomedical HIV prevention interventions (behavioural) are more effective than PrEP (N = 290) Agree 136 (67.7) 79 (88.8) 215 1
Disagree 65 (32.3) 10 (11.2) 75 3.78 (1.84-7.77)
Non-biomedical HIV prevention interventions (behavioural) are safer than PrEP (N = 301) Agree 183 (88.0) 84 (90.3) 267 1
Disagree 25 (12.0) 9 (9.7) 34 1.28 (0.57-2.85)
The use of PrEP will result in less frequent HIV testing among patients (N = 299) Agree 90 (43.7) 52 (55.9) 142 1
Disagree 116 (56.3) 41 (44.1) 157 1.63 (1.00-2.68)
PrEP is too costly (N = 295) Agree 159 (77.6) 78 (86.7) 237 1
Disagree 46 (22.4) 12 (13.3) 58 1.88 (0.94-3.75)
The use of antiretrovirals for prevention will select for, and disseminate, antiretroviral drug resistance (N = 294) Agree 135 (66.5) 68 (74.7) 203 1
Disagree 68 (33.5) 23 (25.3) 91 1.49 (0.85-2.60)
  1. Denominators are reported for each item as non respondents were excluded at univariate analysis; percentages have been calculated on respondents.
  2. * reference sample with different denominator (N = 172); PrEP, Pre-exposure prophylaxis; OR, Odds Ratio.
  3. Boldface = p < 0.05.